|
|
|
|
|
| Efficient Late-Stage Development Of Biologics | White Paper | ProBio | Reducing biological manufacturing costs requires strategic process development, yield optimization, scale-up, and raw material substitute while maintaining product quality and regulatory compliance. |
|
|
|
|
|
|
By Louis Garguilo, chief editor, Outsourced Pharma | Cognitive transfer is a concept widely studied in psychology. Today it has growing relevance within our industry’s ever-increasing technology transfers, which have been understood in the main as moving development/manufacturing processes/technologies from one stage, one location, or one organization – as when utilizing CDMOs – to another. Time now to zero in on the communicating of tacit or implicit knowledge, i.e., knowledge or experience difficult to extract through data or written explanation. This is where cognitive transfer enters our portal. Here is an analysis. | |
|
|
|
INDUSTRY INSIGHTS CONTINUED |
|
|
| Evaluating The Impact Of In-House Testing Strategies | Article | By Kaden Moore, August Bioservices | Rapid analytical testing turnaround is essential to maintaining development timelines, meeting clinical milestones, and in commercial manufacturing, providing reliable drug supply to patients. |
|
|
| How To Double Up With A CDMO To Reduce Risk | Article | Cytiva | Parallel operations with a CDMO can reduce risk and accelerate timelines by enabling simultaneous process development and manufacturing. Learn how this approach supports facility design. |
|
|
| How In-House CDMO Analytics Reduce Risk and Cost | Podcast | 3PBIOVIAN | Uncover why integrated analytics within CDMOs is transforming biopharma: reducing risk, speeding timelines, ensuring data integrity, and preventing costly failures through seamless manufacturing. |
|
|
| Avoid CapEX With Improved Operational Efficiencies | Case Study | Thermo Fisher Scientific Bioproduction | Avoid massive capital expenditures by optimizing supply chain logistics. Learn how off-site material sampling and just-in-time delivery reduce lead times from eight weeks to a single day. |
|
|
| N-1 Perfusion Strategies For Commercial-Ready Biologics | Webinar | Boehringer Ingelheim Biopharmaceuticals GmbH | Assimilate how an approach with modular N-1 perfusion strategies shortens train timelines and reduces facility strain — enabling upstream processes that scale efficiently and reliably. |
|
|
|
| Vial Fogging: Practical Considerations For Vial Selection | White Paper | By Gregory Sacha, Ph.D., and Kevin Bond, Ph.D., Simtra BioPharma Solutions | Vial fogging is a common phenomenon observed in lyophilized biologic drug products. We present two case studies that explore critical factors contributing to vial fogging and inform vial decisions. |
|
|
|
|
|
|
| Join us for two Outsourced Pharma Capabilities Update sessions featuring leading CDMOs sharing their facilities, timelines, and available capacity for development and manufacturing. The April 21st session focuses on small molecule drug product capabilities, while April 22nd highlights fill-finish technologies including sterile filling, lyophilization, and advanced packaging. Expect short digital presentations to help biopharma companies identify partners that can meet their manufacturing needs. Click to learn more. |
|
|
|
|
Scaling Innovations For The Future | | A tech‑driven, integrated ecosystem strengthens TIDES development and scale‑up, enabling reliable progression from early molecular design to commercial delivery as pipelines grow. |
|
|
|
Drug Product Fill And Finish | | Unwrap how comprehensive drug product fill and finish services streamline the journey from formulation development to commercialization, ensuring quality, efficiency, and compliance at every stage. |
|
|
Drug Substance Or API Manufacturing | | We can support discovery, preclinical, clinical, and commercial programs for New Chemical Entities (NCEs). Review our network's API capabilities and contact us to simplify your outsourcing solutions. |
|
|
| Connect With Outsourced Pharma: |
|
|
|
